Status
Conditions
Treatments
About
Idiopathic thrombocytopenic purpura (ITP) is the most frequent auto-immune cytopenia. There is no specific biological marker and the diagnosis often results from the exclusion of other differential diagnoses, notably inherited thrombocytopenia.
Recent studies have reported an original platelet destruction mechanism in ITP, by antibody-mediated desialylation of membrane proteins. The detection of platelet sialylation can be readily achieved using flow cytometry. This could provide a new biomarker of ITP, useful to ascertain a diagnosis of ITP and guide towards proper patient management.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
40 participants in 3 patient groups
There are currently no registered sites for this trial.
Start date
Jan 01, 2018 • 7 years ago
End date
Oct 23, 2019 • 5 years ago
Today
Jan 22, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal